文献速递糖尿病肥胖与代谢综合征

度拉糖肽对2型糖尿病合并NAFLD患者肝脏脂肪的影响:D-LIFT随机对照试验

Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).
PubMed 文献 · Diabetologia · 2020-08-31

D-LIFT是一项在印度三级中心开展的24周开放标签平行组随机对照试验,纳入64例2型糖尿病且MRI-PDFF评估肝脏脂肪含量≥6.0%的成人,比较每周度拉糖肽联合常规治疗与常规治疗。结果显示度拉糖肽组肝脏脂肪含量绝对变化较对照组降低3.5%(95%CI -6.6, -0.4;p=0.025),GGT水平显著下降,胰腺脂肪含量和肝硬度变化不显著,无严重药物相关不良事件。

要点

  • 度拉糖肽每周一次可显著降低2型糖尿病合并NAFLD患者的肝脏脂肪含量。
  • 度拉糖肽还显著降低GGT水平,但AST、ALT、胰腺脂肪和肝硬度变化不显著。
  • 度拉糖肽安全性良好,无严重药物相关不良事件。

核心结论

  • 在2型糖尿病标准治疗基础上加用度拉糖肽可显著降低NAFLD患者的肝脏脂肪含量并改善GGT水平。
  • 胰腺脂肪含量、肝硬度、血清AST和ALT的降低未达统计学显著性。
  • 度拉糖肽可考虑用于2型糖尿病合并NAFLD患者的早期治疗。

研究设计与样本

  • D-LIFT为24周、开放标签、平行组、随机对照试验,在印度一家三级中心开展。
  • 纳入64例2型糖尿病且基线MRI-PDFF评估肝脏脂肪含量≥6.0%的成人,1:1随机分配至度拉糖肽每周一次联合常规治疗组或常规治疗组。
  • 主要终点为两组间从基线至24周肝脏脂肪含量变化的差异;52例参与者纳入符合方案分析。

主要发现

  • 度拉糖肽组肝脏脂肪含量绝对变化较对照组降低3.5%(95%CI -6.6, -0.4;p=0.025),相对变化降低26.4%(95%CI -44.2, -8.6;p=0.004),对应降低幅度为对照组的2.6倍。
  • 度拉糖肽组GGT水平显著下降,组间平均差异为-13.1 U/l(95%CI -24.4, -1.8;p=0.025)。
  • AST变化组间差异为-9.3 U/l(95%CI -19.5, 1.0;p=0.075),ALT变化组间差异为-13.1 U/l(95%CI -24.4, 2.5;p=0.10),均未达统计学显著性。
  • 胰腺脂肪含量绝对变化组间差异为-1.4%(95%CI -3.2, 0.3;p=0.106),肝硬度变化组间差异为-1.31 kPa(95%CI -2.99, 0.37;p=0.123),均不显著。
  • 无严重药物相关不良事件。

临床怎么用

  • 对于2型糖尿病合并NAFLD且肝脏脂肪含量升高的患者,可考虑在常规降糖治疗基础上加用度拉糖肽以降低肝脏脂肪。
  • 度拉糖肽治疗可能有助于改善GGT水平,但对肝硬度、胰腺脂肪及转氨酶的影响尚需进一步研究。

局限性

  • 研究为开放标签设计,样本量较小,符合方案分析仅纳入52例参与者。
  • 研究周期为24周,长期疗效和安全性未评估。
  • 研究在单一印度三级中心开展,结果外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Liraglutide, a daily injectable glucagon-like peptide-1 receptor (GLP-1r) agonist, has been shown to reduce liver fat content (LFC) in humans. Data regarding the effect of dulaglutide, a once-weekly GLP-1r agonist, on human LFC are scarce. This study examined the effect of dulaglutide on LFC in individuals with type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). METHODS: Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India. Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care, based on a predefined computer-generated number with a 1:1 allocation that was concealed using serially numbered, opaque, sealed envelopes. The primary endpoint was the difference of the change in LFC from 0 (baseline) to 24 weeks between groups. The secondary outcome measures included the difference of the change in pancreatic fat content (PFC), change in liver stiffness measurement (LSM in kPa) measured by vibration-controlled transient elastography, and change in liver enzymes. RESULTS: Eighty-eight patients were screened; 32 were randomly assigned to the dulaglutide group and 32 to the control group. Overall, 52 participants were included for per-protocol analysis: those who had MRI-PDFF data at baseline and week 24. Dulaglutide treatment resulted in a control-corrected absolute change in LFC of -3.5% (95% CI -6.6, -0.4; p = 0.025) and relative change of -26.4% (-44.2, -8.6; p = 0.004), corresponding to a 2.6-fold greater reduction. Dulaglutide-treated participants also showed a significant reduction in γ-glutamyl transpeptidase (GGT) levels (mean between-group difference -13.1 U/l [95% CI -24.4, -1.8]; p = 0.025) and non-significant reductions in aspartate aminotransferase (AST) (-9.3 U/l [-19.5, 1.0]; p = 0.075) and alanine aminotransferase (ALT) levels (-13.1 U/l [-24.4, 2.5]; p = 0.10). Absolute changes in PFC (-1.4% [-3.2, 0.3]; p = 0.106) and LSM (-1.31 kPa [-2.99, 0.37]; p = 0.123) were not significant when comparing the two groups. There were no serious drug-related adverse events. CONCLUSIONS/INTERPRETATION: When included in the standard treatment for type 2 diabetes, dulaglutide significantly reduces LFC and improves GGT levels in participants with NAFLD. There were non-significant reductions in PFC, liver stiffness, serum AST and serum ALT levels. Dulaglutide could be considered for the early treatment of NAFLD in patients with type 2 diabetes. TRIAL REGISTRATION: ClinicalTrials.gov NCT03590626 FUNDING: The current study was supported by an investigator-initiated study grant from Medanta-The Medicity's departmental research fund and a grant from the Endocrine and Diabetes Foundation (EDF), India. Graphical abstract.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kuchay MS, Krishan S, Mishra SK, et al. Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial). Diabetologia. 2020. PMID: 32865597. doi:10.1007/s00125-020-05265-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。